Dashboard
1
Poor Management Efficiency with a low ROCE of 1.90%
- The company has been able to generate a Return on Capital Employed (avg) of 1.90% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of 3.56% over the last 5 years
4
Flat results in Jun 25
5
With ROCE of 1.49%, it has a very attractive valuation with a 0.48 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
JPY 11,180 Million (Micro Cap)
1,498.00
NA
0.11%
0.43
-0.94%
0.28
Revenue and Profits:
Net Sales:
15,546 Million
(Quarterly Results - Jun 2025)
Net Profit:
-468 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.76%
0%
-3.76%
6 Months
2.84%
0%
2.84%
1 Year
0.46%
0%
0.46%
2 Years
-13.35%
0%
-13.35%
3 Years
-13.52%
0%
-13.52%
4 Years
-29.27%
0%
-29.27%
5 Years
-51.67%
0%
-51.67%
JMS Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.56%
EBIT Growth (5y)
-17.70%
EBIT to Interest (avg)
4.79
Debt to EBITDA (avg)
3.23
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
1.05
Tax Ratio
98.75%
Dividend Payout Ratio
467.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.90%
ROE (avg)
1.39%
Valuation key factors
Factor
Value
P/E Ratio
1498
Industry P/E
Price to Book Value
0.26
EV to EBIT
32.20
EV to EBITDA
5.91
EV to Capital Employed
0.48
EV to Sales
0.40
PEG Ratio
12.96
Dividend Yield
0.12%
ROCE (Latest)
1.49%
ROE (Latest)
0.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
15,546.00
16,177.00
-3.90%
Operating Profit (PBDIT) excl Other Income
765.00
1,037.00
-26.23%
Interest
84.00
79.00
6.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-468.00
-87.00
-437.93%
Operating Profit Margin (Excl OI)
-11.30%
2.70%
-1.40%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -3.90% vs 10.80% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -437.93% vs 66.92% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
69,749.00
65,292.00
6.83%
Operating Profit (PBDIT) excl Other Income
4,762.00
3,446.00
38.19%
Interest
340.00
220.00
54.55%
Exceptional Items
0.00
0.00
Consolidate Net Profit
7.00
-45.00
115.56%
Operating Profit Margin (Excl OI)
12.50%
-4.10%
1.66%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 6.83% vs 2.43% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 115.56% vs -117.24% in Mar 2024
About JMS Co., Ltd. 
JMS Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






